免疫调节治疗对老年慢性心力衰竭患者的影响研究

目的探讨免疫调节治疗对老年慢性心力衰竭的影响。方法选择我院2011年1月—2012年1月收治的老年慢性心力衰竭(充血性)患者100例,采用随机数字表法分为试验组和对照组,每组50例。两组患者均进行常规治疗和生活方式干预,试验组患者在此基础上加用免疫调节治疗,即胸腺五肽4 mg加入注射用水10 ml肌肉注射,1次/d,15 d为1个疗程,共治疗4个疗程。比较两组患者治疗前后血清TNF-α、IL-10、hs-CRP、IL-1β水平和明尼苏达生活质量量表评分。结果治疗前,两组患者血清TNF-α、IL-10、hs-CRP、IL-1β水平比较,差异均无统计学意义(P0.05);治疗后,试验组患者血清TNF-α、hs-CRP、IL-1β水平低于对照组,血清IL-10水平高于对照组(P0.05)。治疗前,试验组明尼苏达生活质量量表评分为(37.60±15.46)分,对照组为(37.00±15.23)分,差异无统计学意义(t=-0.19,P0.05);治疗后,试验组明尼苏达生活质量量表评分为(27.23±12.45)分,低于对照组的(35.27±14.68)分(t=2.95,P0.05)。结论免疫调节治疗可改善老年慢性心力衰竭患者促炎/抗炎因子失衡状况,提高患者生活质量,是一种治疗新方法。

Effect of Immunotherapy in Old Patients with Chronic Heart Failure

Objective To investigate the effect of immunotherapy in old patients with chronic heart failure（ CHF）. Methods From January 2011 to January 2012 ,100 old patients with congestive CHF were chosen and divided into study group （50 cases）and control group（50 cases）,according to random numeric table method. Patients in both groups given conventional treatment and life intervention,then study group given immunotherapy：muscle injection of thymopentin 4 mg and injection water 10 ml,1 time per day,15 days for a course,and treated for 4 courses. Serum levels of TNF-α,IL-10,hs-CRP,IL-1βand Minnesota life quality scale score between the two groups before and after treatment were compared. Results There was no significant differences in serum levels of TNF-α,IL-10,hs-CRP,IL-1β between the two groups before treatment（ P﹥0. 05）;while serum levels of TNF-α,hs-CRP,IL-1βof study group were lower than those of control group after treatment, serum IL -10 level higher （ P ﹤0. 05 ） . Before treatment, Minnesota life quality scale score of study group was （ 37. 60 ±15.46）,controlgroupwas（37.00±15.23）,thesignificantdifferencewasnotdifferent（t= -0.19,P﹥0.05）.After treatment,Minnesota life quality scale score of study group was（27. 23 ±12. 45）,was lower than that of control group of （35. 27 ±14. 68）（t=2. 95,P﹤0. 05）. Conclusion Immunotherapy,as a new therapy,can rectify the imbalance of proin-flammatory cytokines and anti-inflammatory cytokines,improve the quality of life in old patients with CHF.